Compare EVH & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | IMRX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 322.8M |
| IPO Year | 2015 | 2021 |
| Metric | EVH | IMRX |
|---|---|---|
| Price | $3.03 | $5.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $7.93 | ★ $17.20 |
| AVG Volume (30 Days) | ★ 3.1M | 601.3K |
| Earning Date | 05-20-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | N/A |
| Revenue This Year | $33.03 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $1.10 |
| 52 Week High | $11.92 | $10.08 |
| Indicator | EVH | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 54.25 |
| Support Level | $2.53 | $5.34 |
| Resistance Level | $4.20 | $5.55 |
| Average True Range (ATR) | 0.27 | 0.27 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 43.10 | 60.48 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.